Arpi Minassian1, Brook L Henry2, Jennifer E Iudicello2, Erin E Morgan2, Scott L Letendre3, Robert K Heaton2, William Perry2. 1. Department of Psychiatry, University of California San Diego, La Jolla, CA, United States; Center of Excellence for Stress and Mental Health (CESAMH), Veteran's Administration, San Diego, CA, United States. Electronic address: aminassian@ucsd.edu. 2. Department of Psychiatry, University of California San Diego, La Jolla, CA, United States. 3. Department of Medicine, University of California San Diego, La Jolla, CA, United States.
Abstract
BACKGROUND: Methamphetamine (METH) use is a risk factor for the transmission of HIV. Each is associated with neurocognitive impairment and subsequent problems in everyday functioning, yet additive effects of HIV and METH are not consistently observed. This study used the UCSD Performance-Based Skills Assessment (UPSA-2) to assess whether METH use disorder and HIV together resulted in poorer functional outcome than either condition alone. METHOD: Participants in the Translational Methamphetamine AIDS Research Center (TMARC) cohort were stratified based upon HIV infection and METH use disorder: HIV-/METH- (n=49), HIV-/METH+ (n=48), HIV+/METH- (n=37), and HIV+/METH+ (n=38). They were administered the UPSA-2 which measures abilities in six domains of everyday functioning. Main effects and interactions of HIV and METH were examined, as were relationships between UPSA-2 scores and disease characteristics. RESULTS: Significant HIV-by-METH interactions were observed for the UPSA-2 total score and Comprehension/Planning and Financial subscales such that METH was associated with lower scores in HIV- participants but not HIV+ participants. METH was associated with lower scores on the Communications subscale. All three risk groups had lower scores than HIV-/METH- participants. Recency and frequency of METH use were associated with lower scores. Lower Medication Management scores were related to lower nadir CD4 counts. CONCLUSIONS: METH use disorder and HIV each impair functional performance, but there is no additive effect when the two conditions occur together. The neurocognitive sequelae of combined HIV infection and METH use are complex and warrant further study, as do the potential effects of compensatory strategies and other factors.
BACKGROUND:Methamphetamine (METH) use is a risk factor for the transmission of HIV. Each is associated with neurocognitive impairment and subsequent problems in everyday functioning, yet additive effects of HIV and METH are not consistently observed. This study used the UCSD Performance-Based Skills Assessment (UPSA-2) to assess whether METH use disorder and HIV together resulted in poorer functional outcome than either condition alone. METHOD:Participants in the Translational MethamphetamineAIDS Research Center (TMARC) cohort were stratified based upon HIV infection and METH use disorder: HIV-/METH- (n=49), HIV-/METH+ (n=48), HIV+/METH- (n=37), and HIV+/METH+ (n=38). They were administered the UPSA-2 which measures abilities in six domains of everyday functioning. Main effects and interactions of HIV and METH were examined, as were relationships between UPSA-2 scores and disease characteristics. RESULTS: Significant HIV-by-METH interactions were observed for the UPSA-2 total score and Comprehension/Planning and Financial subscales such that METH was associated with lower scores in HIV- participants but not HIV+ participants. METH was associated with lower scores on the Communications subscale. All three risk groups had lower scores than HIV-/METH- participants. Recency and frequency of METH use were associated with lower scores. Lower Medication Management scores were related to lower nadirCD4 counts. CONCLUSIONS:METH use disorder and HIV each impair functional performance, but there is no additive effect when the two conditions occur together. The neurocognitive sequelae of combined HIV infection and METH use are complex and warrant further study, as do the potential effects of compensatory strategies and other factors.
Authors: David J Moore; Kaitlin Blackstone; Steven Paul Woods; Ronald J Ellis; J Hampton Atkinson; Robert K Heaton; Igor Grant Journal: AIDS Care Date: 2012-04-24
Authors: J Cobb Scott; Steven Paul Woods; Georg E Matt; Rachel A Meyer; Robert K Heaton; J Hampton Atkinson; Igor Grant Journal: Neuropsychol Rev Date: 2007-09 Impact factor: 7.444
Authors: Kate Buchacz; Willi McFarland; Timothy A Kellogg; Lisa Loeb; Scott D Holmberg; James Dilley; Jeffrey D Klausner Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Jennifer E Iudicello; Erin E Morgan; Assawin Gongvatana; Scott L Letendre; Igor Grant; Steven Paul Woods Journal: J Neurovirol Date: 2014-01-28 Impact factor: 2.643
Authors: Arpi Minassian; Jared W Young; Zackary A Cope; Brook L Henry; Mark A Geyer; William Perry Journal: Psychopharmacology (Berl) Date: 2015-10-09 Impact factor: 4.530
Authors: T Jordan Walter; Jared W Young; Morgane Milienne-Petiot; D S Deben; Robert K Heaton; Scott Letendre; David J Grelotti; William Perry; Igor Grant; Arpi Minassian Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2020-09-04 Impact factor: 5.067